Nothing Special   »   [go: up one dir, main page]

USRE32011E - Ultrapurification of factor VIII using monoclonal antibodies - Google Patents

Ultrapurification of factor VIII using monoclonal antibodies Download PDF

Info

Publication number
USRE32011E
USRE32011E US06/563,795 US56379583A USRE32011E US RE32011 E USRE32011 E US RE32011E US 56379583 A US56379583 A US 56379583A US RE32011 E USRE32011 E US RE32011E
Authority
US
United States
Prior art keywords
viii
iaddend
iadd
human
immunoadsorbent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/563,795
Inventor
Theodore S. Zimmerman
Carol A. Fulcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Clinic and Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE32011(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/330,105 external-priority patent/US4361509A/en
Application filed by Scripps Clinic and Research Foundation filed Critical Scripps Clinic and Research Foundation
Priority to US06/563,795 priority Critical patent/USRE32011E/en
Application granted granted Critical
Publication of USRE32011E publication Critical patent/USRE32011E/en
Assigned to SCRIPPS RESEARCH INSTITUTE, THE, A CORP. OF CA reassignment SCRIPPS RESEARCH INSTITUTE, THE, A CORP. OF CA ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: SCRIPPS CLINIC AND RESEARCH FOUNDATION
Priority to MX9203820A priority patent/MX9203820A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present method also permits the selection of a monoclonal antibody having a high affinity for VIII:RP; however, the use of polyclonal antibodies results in varying affinities. It should be realized that there is an indirect relationship between the affinity of the bound antibody for VIII:RP and the elution of VIII:RP. Thus, the higher the affinity of the antibody for VIII:RP, the less VIII:RP will be present with VIII:C in the eluant.
  • the present invention also makes it possible to produce an unlimited supply of the specified monoclonal antibody, thus eliminating variations among different batches.
  • the present method yields VIII:C with a specific activity of 2,300 units/mg when commercial concentrate is used. This corresponds to a 164,000 fold purification from plasma.
  • the ratio of VIII:C to VIII:RP is greater than 10 5 as compared to the ratio in plasma.
  • the monoclonal antibody to VIII:RP which is subsequently bound to the separation substrate may be prepared in a stepwise procedure starting with a highly purified preparation of factor VIII/von Willebrand factor (VIII:C/VIII:RP complex).
  • the purification for immunization is accomplished with material obtained from a plasma source. Less highly purified material for coating polyvinyl plates is obtained in higher concentration from commercial extracts such as FACTORATE (trademark of Armour Pharmaceutical Co., Tuckahoe, N.Y.) or Hemophil (trademark of Hyland Laboratories, Costa Mesa, California).
  • mice are injected intraperitoneally with a composition prepared by dissolving (or suspending) 10 Mg of the protein in 0.1 ml of buffer containing 0.05 M Tris, 0.15 M sodium chloride, 0.02 % sodium azide, 1 mM phenyl methyl sulfonyl fluoride, traysylol 10 units/ml at pH7.3. and shaking with an equal volume of complete Freund's adjuvant.
  • the mice are again injected with the same material except that incomplete Freund's adjuvant is substituted for complete Freund's adjuvant.
  • the injection of day 14 is repeated.
  • the mice are injected with purified VIII:C/VIII:RP only.
  • mice On day 42, the spleens of the mice are removed and fused according to a standard procedure, of the type described by J. P. Brown et al "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 225, pp. 4980-4983 (1980).
  • the standard technique is varied only to the extent that 35% polyethylene glycol 1000 is substituted for 50% polyethylene glycol.
  • a radioimmunoassay method for clones producing antibody to VIII:RP is performed according to the following procedure.
  • Polyvinyl plates with a "V" bottom, flexible type are coated with 0.1 ml of factor VIII purified from commercial extract according to the procedure indicated above and having a concentration of 0.125 mg/ml of protein.
  • the plates are blocked with albumin, washed with buffer and incubated with the culture fluids from the clones to be tested.
  • the plates are then washed and reacted with rabbit anti-mouse IgG antiserum, washed a second time and 125 I labeled goat anti-rabbit IgG antiserum is added to the wells and incubated. The plates are again washed, then dried and the wells cut-out and counted.
  • mice After determining the clones which are positive they are subcloned at least twice and stable clones producing antibody to VIII:RP are then injected into the peritoneal cavities of Balb/C mice which have been pretreated intraperitoneally with 0.5 ml of pristane at least four days prior to injection of cells.
  • Hybridoma cells are injected at concentrations of approximately 5 ⁇ 10 6 cells per mouse in 0.5 ml of Delbecco's modified Eagle's medium without fetal bovine serum. The mice are tapped when bloated and ascites fluid is collected in heparin at approximately 10 units/ml. Ascites fluid from multiple mice is pooled to provide a convenient volume for subsequent isolation of the monoclonal IgG.
  • the heparinized ascites fluid may be stored at -70° C. and thawed just prior to use.
  • the final yield of IgG from the ascites fluid is approximately 1 g of IgG per 100 ml of ascites fluid.
  • the specificity of the monoclonal IgG for the purpose of purifying VIII:C may be assessed by coupling the IgG to a separation substrate medium, in the manner described hereinafter, and demonstrating that the bound IgG removes from VIII:RP and VIII:C from plasma and that the VIII:C may be subsequently eluted with a solution containing calcium ions while the VIII:RP remains complexed to the monoclonal IgG which is bound to the solid-state substrate.
  • the monoclonal IgG which is to be used subsequently to prepare the immunoadsorbent, may be isolated from heparinized pooled ascites fluid immediately after collection or a frozen portion of the stored solution may be thawed. Regardless of whether fresh or frozen material is used, the solution is brought to 4° C. and treated with an equal volume of phosphate buffered saline solution (PBS), the composition of which is set forth below. The diluted ascites is precipitated by dropwise addition with stirring at 4° C.
  • PBS phosphate buffered saline solution
  • SAS saturated ammonium sulfate
  • the pellets resulting from the third precipitation are resuspended in a volume of PBS equal to that of the diluted ascites fluid and then disalyzed exhaustively against PBS. Clots appearing in the dialysis bags are removed by centrifugation at 20° C.
  • the dialyzed IgG is adsorbed by stirring it with a 5% aqueous solution of aluminum hydroxide at room temperature and centrifuging at 20° C. after adsorption. The adsorption treatment is repeated at least three more times using 2.5% aluminum hydroxide solution for each treatment after the first.
  • the adsorbed IgG is brought to 4° C. and reprecipitated once with SAS as described above.
  • the precipitated pellets may be stored at -20° C. until used.
  • the immunoadsorbent is prepared by suitably preparing the monoclonal IgG for coupling, preparing the solid substrate for coupling and reacting the two components to bind the former to the later.
  • IgG Either freshly precipitated IgG may be used or previously frozen precipitate may be thawed for use.
  • the IgG is then treated with between 10 and 30 microliters, preferably 20 microliters, or diisopropylfluorophosphate per 50 ml of IgG solution.
  • the resulting solution is stirred at room temperature in a hood for 30 minutes and the treated IgG, immediately prior to use, is dialyzed overnight against coupling buffer.
  • the coupling buffer found most suitable is a 0.25 M sodium bicarbonate solution adjusted to a pH of 9, preferably with sodium hydroxide.
  • the monoclonal antibody may be bound to any material which does not have a high affinity for protein, particularly factor VIII itself, such materials as glass beads, agarose and derivatives thereof are preferred. Most preferred is a crosslinked agarose available commercially as a gel known as Sepharose CL2B (trademark of Pharmacia Fine Chemicals, Piscataway, N.J.).
  • the method of preparing the preferred immunoadsorbent resin is generally the same as that disclosed in the literature, such as the method of J. Porath et al, JOURNAL OF CHROMATOGRAPHY, Vol. 86, pp. 53-56 (1973).
  • the method found most suitable is as follows: a volume of about 2 liters of Sepharose CL2B is placed in an acid-cleaned 2 liter sintered glass filter funnel. The resin is washed with water and filtered to a moist cake. The washed resin is placed in a large (approximately 4 liter) glass beaker equipped with a magnetic stirring bar.
  • cold potassium phosphate buffer solution prepared by mixing one part of a 5 M dibasic potassium phosphate solution with two parts of 5 M tribasic potassium phosphate solution. Sufficient cold water is added to bring the final volume to 3 liters. The mixture is then chilled to 4° C. and maintained at between 4°-10° C. in an ice-water bath placed on a magnetic stirring plate. In a hood, cyanogen bromide is added to 300 ml of water in a stoppered glass bottle containing a magnetic stirring bar. The mixture is rapidly stirred until solution results. The cyanogen bromide solution is then added with stirring over a 2 minute period to the cold Sepharose mixture.
  • the solid substrate resin prepared as indicated above, is ready to be used when it is equilbrated with coupling buffer and should not be stored thereafter. Accordingly, the resin mixture is combined with the IgG which was previously dialyzed overnight against coupling buffer. The combined resin/IgG suspended mixture is stirred at 4° C. for a period of about 24 hours.
  • the A 280 of an undiluted sample of the supernatant coupling liquid may be determined using bovine serum albumin (BSA) as a standard or Bio-Rad protein assay (Bradford reagent) with BSA as standard. The percentage ligand which is coupled may then be calculated. When the above described procedure is followed, this is usually about 95%.
  • any remaining active sites on the resin not coupled to antibody may be blocked by washing the resin on a sintered glass filter funnel with cold coupling buffer containing 0.1 M glycine.
  • the resin is then resuspended in this solution to a final volume equal to that when the resin and antibody, each in coupling buffer, were combined.
  • the suspension is stirred slowly overnight at 4° C.
  • the resin is then washed thoroughly with VIII:C-buffer, the composition of which is given below.
  • the coupled, blocked resin is then pre-eluted with VIII:C-buffer additionally containing 0.5 M calcium ions, preferably calcium chloride.
  • the resin is again washed with VIII:C buffer alone and stored at 4° C. or in a continuously pumped column at room temperature until ready for use.
  • the coupling density of IgG to SEPHAROSE should be 2-5 g, preferably 3-4 g IgG/liter of SEPHAROSE.
  • sample preparation of factor VIII such as human and animal plasmas and commercial concentrates of factor VIII
  • the method is not limited as to a particular type of material.
  • Preferred materials, and those which have demonstrated successful results are porcine and human plasmas and commercially available concentrates of human factor VIII, such as FACTORATE available from Armour Pharmaceutical Co. The following description provides details for using both porcine plasma or commercial human concentrate such as FACTORATE:
  • FACTORATE is reconstituted by adding 25 ml portions of VIII:C-buffer to the contents of each of 20 bottles containing 400-500 VIIIC units per bottle (25 ml per bottle). The mixture is adjusted to a final volume of 1 liter with VIII:C-buffer. A sample aliquot of 0.5 ml may be removed for assay and the remaining material applied to the immunoadsorbent column overnight at a rate of approximately 60 ml/hour.
  • Porcine plasma when not freshly drawn, is citrated by conventional means and stored frozen. When ready to be used it is thawed at a temperature of between 35°-40° C., preferably 37° C. and applied directly to the column at 60 ml/hour.
  • the resin is placed in a column, such as an Amicon 86001, (trademark of Amicon Corp., Lexington, Mass.), equipped with a peristaltic pump and a high flow head.
  • a column such as an Amicon 86001, (trademark of Amicon Corp., Lexington, Mass.), equipped with a peristaltic pump and a high flow head.
  • concentrate is used as the source of factor VIII, for 20 bottles of diluted concentrate, approximately 1.5 liters of resin, prepared as indicated above, is used.
  • porcine plasma 150 ml of resin is used for each liter of plasma.
  • VIII:C-buffer containing calcium ions.
  • a linear gradient as taught by Tuddenham et al, supra, works well, it is not required in order to accomplish the object of this invention; a solution having a fixed calcium ion concentration is quite adequate.
  • VIII:C-buffer 0.25 to 0.5 M with respect to calcium chloride, preferably 0.35 M, is used advantageously as a flow rate of between 450 to 750 ml/hour and preferably 600 ml/hour.
  • VIII:C-buffer being a calcium chloride concentration of between 0.35 and 0.7 M, preferably 0.5 M and at a flow rate of between 10 and 30 ml/hour, preferably 20 ml/hour.
  • Fractions of 12 ml and 3 ml are collected for VIII:C originating from concentrate and porcine plasma, respectively. Those fractions containing at least 1.0 unit/ml of VIII:C activity are pooled and the total volume and activity of the pool determined.
  • the VIII:C pool is initially concentrated to 10-20 ml by a standard procedure such as pressure ultrafiltration.
  • a standard procedure such as pressure ultrafiltration.
  • Amicon stirred cell in which a YM-10 membrane under 50 psi of nitrogen pressure has been found to work well. Slow stirring is continued for 30 minutes after nitrogen pressure is released, and the volume and activity of the concentrated pool are determined.
  • the pool may be stored for a brief period, that is, overnight for example, if a temperature of 4° C. is maintained.
  • the immunoadsorbent column described above may be regenerated by treatment of the column with 2 bed volumes of 3 M aqueous sodium thiocyanate solution run at a flow rate of about 0.5-1 liter/hour to elute VIII:RP.
  • Aminohexyl agarose is agarose which has been reacted with 1,6-diaminohexane to yield an agarose resin having a number of 6 carbon atom chains, each of which has a terminal amino group. It may be prepared according to the method described by Austen, supra, or acquired from a commercial supplier. One such material which has been used successfully in the present invention is available under the name of AH-SEPHAROSE 4B (trademark of Pharmacia Fine Chemicals, Piscataway, N.J.).
  • the resin should be conditioned prior to use. This may be accomplished as follows, the volumes, amounts and dimensions being adjusted in proportion to the amount of material to be concentrated:
  • the concentrated pool prepared as described above, is diluted 1:10 in VIII:C-buffer to a final concentration of 100-200 ml when using the amounts of resin and column size as described in the immediately preceding section.
  • the diluted pool is applied to the column at a flow rate of 200 ml/hour.
  • the column is then washed with VIII:C-buffer which contains calcium ions, preferably from calcium chloride.
  • the solution should be between 0.01 M to 0.03 M, preferably 0.025 M with respect to calcium ions.
  • Elution of the concentrated VIII:C is achieved at a flow rate of between 5 to 20 ml/hour, preferably 10 ml/hour with VIII:C-buffer containing a higher concentration of calcium ions than was employed with the preceding washing step.
  • calcium chloride is the preferred source of calcium ions in a concentration of between 0.25 to 0.5 M, preferably 0.3 M.
  • Assays may be performed by diluting the fractions with VIII-C buffer if necessary and further diluting the fraction 1:100 in assay buffer prior to addition to the substrate.
  • a standard partial thromboplastin time assay is employed.
  • composition of the buffer solutions is as follows:
  • pH of buffer is 7.2
  • pH of buffer is adjusted with concentrated hydrochloric acid to 6.8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

10-20 units of VIII:C per ml of eluant are obtained with the present invention, in contract to 0.5-1.25 units per ml of eluant with the Tuddenham et al method.
The present method also permits the selection of a monoclonal antibody having a high affinity for VIII:RP; however, the use of polyclonal antibodies results in varying affinities. It should be realized that there is an indirect relationship between the affinity of the bound antibody for VIII:RP and the elution of VIII:RP. Thus, the higher the affinity of the antibody for VIII:RP, the less VIII:RP will be present with VIII:C in the eluant. The present invention also makes it possible to produce an unlimited supply of the specified monoclonal antibody, thus eliminating variations among different batches.
Although Austen, as earlier described, has reported the use of aminohexyl-agarose to separate VIII:C from VIII:RP, such a material has not heretofore been used to concentrate VIII:C following a separation and purification step. Heretofore, the highest VIII:C concentrations achieved by using aminohexyl agarose in chromatography were 0.53 units per ml of eluant for human protein and 2.38 per ml of eluant for porcine VIII:C. The present method permits concentrations several orders of magnitude greater than these. Perhaps of even greater significance, is the fact that the present invention provides for a greater purification of human VIII:C than has ever been reported (164,000 vs 17,000 fold over plasma). The present method, which is described in more detail hereinafter, yields VIII:C with a specific activity of 2,300 units/mg when commercial concentrate is used. This corresponds to a 164,000 fold purification from plasma. The ratio of VIII:C to VIII:RP is greater than 105 as compared to the ratio in plasma.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following description provides details of the manner in which the embodiments of the present invention may be made and used in order to achieve the separation, purification and concentration of VIII:C to a degree of purity and concentration not known heretofore. This description, while exemplary of the present invention, is not to be construed as specifically limiting the invention and such variations which would be within the purview of one skilled in this art are to be considered to fall within the scope of this invention.
A. Preparation of Monoclonal Antibody to VIII:RP
The monoclonal antibody to VIII:RP which is subsequently bound to the separation substrate may be prepared in a stepwise procedure starting with a highly purified preparation of factor VIII/von Willebrand factor (VIII:C/VIII:RP complex). The purification for immunization is accomplished with material obtained from a plasma source. Less highly purified material for coating polyvinyl plates is obtained in higher concentration from commercial extracts such as FACTORATE (trademark of Armour Pharmaceutical Co., Tuckahoe, N.Y.) or Hemophil (trademark of Hyland Laboratories, Costa Mesa, California). Purification is performed by a standard agarose-gel filtration of cryoprecipitate, such as that described by Zimmerman and Roberts, "Factor VIII Related Antigen", appearing in IMMUNOASSAYS: CLINICAL LABORATORY TECHNIQUES FOR THE 1980's, R. M. Nakamura et al, eds., Alan R. Liss, Inc., New York, pp. 339-349 (1980). Mice were injected with highly purified factor VIII/von Willebrand factor obtained from plasma according to the following procedure. On day zero, the mice are injected intraperitoneally with a composition prepared by dissolving (or suspending) 10 Mg of the protein in 0.1 ml of buffer containing 0.05 M Tris, 0.15 M sodium chloride, 0.02 % sodium azide, 1 mM phenyl methyl sulfonyl fluoride, traysylol 10 units/ml at pH7.3. and shaking with an equal volume of complete Freund's adjuvant. On day 14, the mice are again injected with the same material except that incomplete Freund's adjuvant is substituted for complete Freund's adjuvant. On day 21, the injection of day 14 is repeated. On day 38, the mice are injected with purified VIII:C/VIII:RP only. On day 42, the spleens of the mice are removed and fused according to a standard procedure, of the type described by J. P. Brown et al "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 225, pp. 4980-4983 (1980). The standard technique is varied only to the extent that 35% polyethylene glycol 1000 is substituted for 50% polyethylene glycol. A radioimmunoassay method for clones producing antibody to VIII:RP is performed according to the following procedure. Polyvinyl plates with a "V" bottom, flexible type are coated with 0.1 ml of factor VIII purified from commercial extract according to the procedure indicated above and having a concentration of 0.125 mg/ml of protein. The plates are blocked with albumin, washed with buffer and incubated with the culture fluids from the clones to be tested. The plates are then washed and reacted with rabbit anti-mouse IgG antiserum, washed a second time and 125 I labeled goat anti-rabbit IgG antiserum is added to the wells and incubated. The plates are again washed, then dried and the wells cut-out and counted. After determining the clones which are positive they are subcloned at least twice and stable clones producing antibody to VIII:RP are then injected into the peritoneal cavities of Balb/C mice which have been pretreated intraperitoneally with 0.5 ml of pristane at least four days prior to injection of cells. Hybridoma cells are injected at concentrations of approximately 5×106 cells per mouse in 0.5 ml of Delbecco's modified Eagle's medium without fetal bovine serum. The mice are tapped when bloated and ascites fluid is collected in heparin at approximately 10 units/ml. Ascites fluid from multiple mice is pooled to provide a convenient volume for subsequent isolation of the monoclonal IgG. If the heparinized ascites fluid is not used immediately, it may be stored at -70° C. and thawed just prior to use. The final yield of IgG from the ascites fluid is approximately 1 g of IgG per 100 ml of ascites fluid.
The specificity of the monoclonal IgG for the purpose of purifying VIII:C may be assessed by coupling the IgG to a separation substrate medium, in the manner described hereinafter, and demonstrating that the bound IgG removes from VIII:RP and VIII:C from plasma and that the VIII:C may be subsequently eluted with a solution containing calcium ions while the VIII:RP remains complexed to the monoclonal IgG which is bound to the solid-state substrate.
The monoclonal IgG, which is to be used subsequently to prepare the immunoadsorbent, may be isolated from heparinized pooled ascites fluid immediately after collection or a frozen portion of the stored solution may be thawed. Regardless of whether fresh or frozen material is used, the solution is brought to 4° C. and treated with an equal volume of phosphate buffered saline solution (PBS), the composition of which is set forth below. The diluted ascites is precipitated by dropwise addition with stirring at 4° C. of an equal volume of saturated ammonium sulfate (SAS); prepared by boiling an excess of ammonium sulfate in water, cooling to 4° C., filtering undissolved crystals and adjusting the pH to 7.0 with ammonium hydroxide. The precipitate and its supernatant liquid are stirred for at least 2 hours and centrifuged at 4° C. Centrifugations are preferably carried out at 14,000 rpm for 60 minutes (30,000×g). The supernatant solution of ascites is precipitated twice more with SAS and the mixture of precipitate and supernatant liquid stirred and centrifuged in the same manner as in the first cycle. The pellets resulting from the third precipitation are resuspended in a volume of PBS equal to that of the diluted ascites fluid and then disalyzed exhaustively against PBS. Clots appearing in the dialysis bags are removed by centrifugation at 20° C. The dialyzed IgG is adsorbed by stirring it with a 5% aqueous solution of aluminum hydroxide at room temperature and centrifuging at 20° C. after adsorption. The adsorption treatment is repeated at least three more times using 2.5% aluminum hydroxide solution for each treatment after the first. The adsorbed IgG is brought to 4° C. and reprecipitated once with SAS as described above. The precipitated pellets may be stored at -20° C. until used.
B. Preparation of the Immunoadsorbent
The immunoadsorbent is prepared by suitably preparing the monoclonal IgG for coupling, preparing the solid substrate for coupling and reacting the two components to bind the former to the later.
(i) Preparation of IgG for Coupling
Either freshly precipitated IgG may be used or previously frozen precipitate may be thawed for use. The material is then dialyzed against PBS, and while still in the PBS, the volume and IgG concentration (A280 /1.4=mg/ml IgG) are determined. The IgG is then treated with between 10 and 30 microliters, preferably 20 microliters, or diisopropylfluorophosphate per 50 ml of IgG solution. The resulting solution is stirred at room temperature in a hood for 30 minutes and the treated IgG, immediately prior to use, is dialyzed overnight against coupling buffer. The coupling buffer found most suitable is a 0.25 M sodium bicarbonate solution adjusted to a pH of 9, preferably with sodium hydroxide.
(ii) Preparation of Solid Substrate for Coupling
Although the monoclonal antibody may be bound to any material which does not have a high affinity for protein, particularly factor VIII itself, such materials as glass beads, agarose and derivatives thereof are preferred. Most preferred is a crosslinked agarose available commercially as a gel known as Sepharose CL2B (trademark of Pharmacia Fine Chemicals, Piscataway, N.J.).
The method of preparing the preferred immunoadsorbent resin is generally the same as that disclosed in the literature, such as the method of J. Porath et al, JOURNAL OF CHROMATOGRAPHY, Vol. 86, pp. 53-56 (1973). The method found most suitable is as follows: a volume of about 2 liters of Sepharose CL2B is placed in an acid-cleaned 2 liter sintered glass filter funnel. The resin is washed with water and filtered to a moist cake. The washed resin is placed in a large (approximately 4 liter) glass beaker equipped with a magnetic stirring bar. To the resin is then added 750 ml of cold potassium phosphate buffer solution, prepared by mixing one part of a 5 M dibasic potassium phosphate solution with two parts of 5 M tribasic potassium phosphate solution. Sufficient cold water is added to bring the final volume to 3 liters. The mixture is then chilled to 4° C. and maintained at between 4°-10° C. in an ice-water bath placed on a magnetic stirring plate. In a hood, cyanogen bromide is added to 300 ml of water in a stoppered glass bottle containing a magnetic stirring bar. The mixture is rapidly stirred until solution results. The cyanogen bromide solution is then added with stirring over a 2 minute period to the cold Sepharose mixture. Stirring is continued for an additional 8 minutes and then transferred to a chilled 2 liter sintered glass filter funnel supported in a 4 liter vacuum flask. The cyanogen bromide treated resin is then washed with approximately 20 liters of cold water or until the pH of the filtrate is neutral. The washed resin is then quickly equilibrated with cold coupling buffer and then transferred to a 4 liter plastic beaker equipped with a large magnetic stirring bar.
(iii) Coupling the Monoclonal Antibody to the Solid Substrate
The solid substrate resin, prepared as indicated above, is ready to be used when it is equilbrated with coupling buffer and should not be stored thereafter. Accordingly, the resin mixture is combined with the IgG which was previously dialyzed overnight against coupling buffer. The combined resin/IgG suspended mixture is stirred at 4° C. for a period of about 24 hours. The A280 of an undiluted sample of the supernatant coupling liquid may be determined using bovine serum albumin (BSA) as a standard or Bio-Rad protein assay (Bradford reagent) with BSA as standard. The percentage ligand which is coupled may then be calculated. When the above described procedure is followed, this is usually about 95%. Any remaining active sites on the resin not coupled to antibody may be blocked by washing the resin on a sintered glass filter funnel with cold coupling buffer containing 0.1 M glycine. The resin is then resuspended in this solution to a final volume equal to that when the resin and antibody, each in coupling buffer, were combined. The suspension is stirred slowly overnight at 4° C. The resin is then washed thoroughly with VIII:C-buffer, the composition of which is given below. The coupled, blocked resin is then pre-eluted with VIII:C-buffer additionally containing 0.5 M calcium ions, preferably calcium chloride. The resin is again washed with VIII:C buffer alone and stored at 4° C. or in a continuously pumped column at room temperature until ready for use. The coupling density of IgG to SEPHAROSE should be 2-5 g, preferably 3-4 g IgG/liter of SEPHAROSE.
C. Separation and Purification of VIII:C
(i) Sample preparation of factor VIII, such as human and animal plasmas and commercial concentrates of factor VIII, may be employed in the present invention and the method is not limited as to a particular type of material. Preferred materials, and those which have demonstrated successful results, are porcine and human plasmas and commercially available concentrates of human factor VIII, such as FACTORATE available from Armour Pharmaceutical Co. The following description provides details for using both porcine plasma or commercial human concentrate such as FACTORATE:
FACTORATE is reconstituted by adding 25 ml portions of VIII:C-buffer to the contents of each of 20 bottles containing 400-500 VIIIC units per bottle (25 ml per bottle). The mixture is adjusted to a final volume of 1 liter with VIII:C-buffer. A sample aliquot of 0.5 ml may be removed for assay and the remaining material applied to the immunoadsorbent column overnight at a rate of approximately 60 ml/hour.
Porcine plasma, when not freshly drawn, is citrated by conventional means and stored frozen. When ready to be used it is thawed at a temperature of between 35°-40° C., preferably 37° C. and applied directly to the column at 60 ml/hour.
It should be noted that while the description of the present invention refers, and is directed primarily, to the use of immunoadsorbent coupled particles in a chromatography column, it is within the scope of this invention to perform batchwise separations by placing the antibody-bound resin particles in a suitable container and after adding reconstituted concentrate or plasma, VIII:C as outlined above and described in more detail below.
When the process is carried out in a chromatography process, the following embodiments are preferred:
The resin is placed in a column, such as an Amicon 86001, (trademark of Amicon Corp., Lexington, Mass.), equipped with a peristaltic pump and a high flow head. When concentrate is used as the source of factor VIII, for 20 bottles of diluted concentrate, approximately 1.5 liters of resin, prepared as indicated above, is used. When porcine plasma is used, 150 ml of resin is used for each liter of plasma.
After the sample is applied to the column, it is washed with 1 liter of VIII:C-buffer, followed by a second washing with VIII:C-buffer which additionally contains 0.5 M NaCl. Approximately 20 liters of saline-buffer is used when factor VIII is applied as concentrate and 20 bed volumes when porcine plasma is employed. Optimum results are obtained with a flow rate of 1 liter/hour.
Elution of purified VIII:C is accomplished with VIII:C-buffer containing calcium ions. Although a linear gradient, as taught by Tuddenham et al, supra, works well, it is not required in order to accomplish the object of this invention; a solution having a fixed calcium ion concentration is quite adequate. Thus, when VIII:C derived from concentrate is being eluted, VIII:C-buffer, 0.25 to 0.5 M with respect to calcium chloride, preferably 0.35 M, is used advantageously as a flow rate of between 450 to 750 ml/hour and preferably 600 ml/hour. When the VIII:C is obtained from porcine plasma, elution is performed with VIII:C-buffer being a calcium chloride concentration of between 0.35 and 0.7 M, preferably 0.5 M and at a flow rate of between 10 and 30 ml/hour, preferably 20 ml/hour. Fractions of 12 ml and 3 ml are collected for VIII:C originating from concentrate and porcine plasma, respectively. Those fractions containing at least 1.0 unit/ml of VIII:C activity are pooled and the total volume and activity of the pool determined.
The VIII:C pool is initially concentrated to 10-20 ml by a standard procedure such as pressure ultrafiltration. For this purpose, Amicon stirred cell in which a YM-10 membrane under 50 psi of nitrogen pressure has been found to work well. Slow stirring is continued for 30 minutes after nitrogen pressure is released, and the volume and activity of the concentrated pool are determined. The pool may be stored for a brief period, that is, overnight for example, if a temperature of 4° C. is maintained.
It may be noted that the immunoadsorbent column described above may be regenerated by treatment of the column with 2 bed volumes of 3 M aqueous sodium thiocyanate solution run at a flow rate of about 0.5-1 liter/hour to elute VIII:RP.
D. Concentration of Purified VIII:C
Although the VIII:C recovered from the separation from VIII:RP by means of the immunoadsorbent column is highly purified, it is still too dilute to be therapeutically useful. Further concentration and a four fold increase in purification when porcine plasma is used is accomplished by use of an aminohexyl agarose column which is prepared and used in the following manner:
(i) Preparation and/or Conditioning of a Aminohexyl Agarose Column:
Aminohexyl agarose is agarose which has been reacted with 1,6-diaminohexane to yield an agarose resin having a number of 6 carbon atom chains, each of which has a terminal amino group. It may be prepared according to the method described by Austen, supra, or acquired from a commercial supplier. One such material which has been used successfully in the present invention is available under the name of AH-SEPHAROSE 4B (trademark of Pharmacia Fine Chemicals, Piscataway, N.J.).
Whether prepared or purchased, the resin should be conditioned prior to use. This may be accomplished as follows, the volumes, amounts and dimensions being adjusted in proportion to the amount of material to be concentrated:
Approximately 1 gram of aminohexyl agarose (AH-SEPHAROSE 4B) is placed in a sintered glass filter funnel and washed with at least 200 ml of 0.5 M sodium chloride, while stirring. The resin is then equilibrated with VIII:C-buffer and packed in a column of approximately 0.9 cm diameter. A Bio-Rad Econo-Column with flow adapters has proven quite suitable for the type of use considered here. The bed volume of the packed column is approximately 4 ml.
(ii) Application to and Use of the Aminohexyl Agarose Column
The concentrated pool, prepared as described above, is diluted 1:10 in VIII:C-buffer to a final concentration of 100-200 ml when using the amounts of resin and column size as described in the immediately preceding section. The diluted pool is applied to the column at a flow rate of 200 ml/hour.
The column is then washed with VIII:C-buffer which contains calcium ions, preferably from calcium chloride. The solution should be between 0.01 M to 0.03 M, preferably 0.025 M with respect to calcium ions.
Elution of the concentrated VIII:C is achieved at a flow rate of between 5 to 20 ml/hour, preferably 10 ml/hour with VIII:C-buffer containing a higher concentration of calcium ions than was employed with the preceding washing step. Again, calcium chloride is the preferred source of calcium ions in a concentration of between 0.25 to 0.5 M, preferably 0.3 M. Fractions of 1 ml volume are collected and assayed as described below. Collected fractions may be stored at 4° C. or frozen. Preparations of VIII:C obtained from a porcine plasma source should be stabilized within 5 to 10% human serum albumin prior to storage.
Assays may be performed by diluting the fractions with VIII-C buffer if necessary and further diluting the fraction 1:100 in assay buffer prior to addition to the substrate. A standard partial thromboplastin time assay is employed.
The composition of the buffer solutions is as follows:
Phosphate Buffered Saline Solution:
1.6 g sodium phosphate, monobasic monohydrate
8.4 g sodium phosphate, dibasic anhydrous
61.4 sodium chloride
Water to 7 liters
pH of buffer is 7.2
VIII:C-Buffer
ml 0.02 M imidazole
ml 0.15 M sodium chloride
ml 0.10 M lysine
ml 0.02% sodium azide
pH of buffer is adjusted with concentrated hydrochloric acid to 6.8.
The data listed hereinafter in Tables I and II are representative of that obtained according to the present invention, as described above.
                                  TABLE I                                 
__________________________________________________________________________
VIII:C Obtained From FACTORATE Concentrate as the Source of               
VIII:C/VIII:RP                                                            
                                         Specific                         
                                              From                        
                VIIIC                                                     
                    VIIIC                Activity                         
                                              Plasma                      
           Volume                                                         
                (Units/                                                   
                    (Total                                                
                        Protein                                           
                             Protein                                      
                                   Recovery                               
                                         (Units/                          
                                              (Fold                       
           (ml) ml)*                                                      
                    Units)                                                
                        (mg/ml)                                           
                             (Total mg)                                   
                                   (%)   mg)  Purif.)                     
__________________________________________________________________________
Sample Applied to                                                         
           500  18.8                                                      
                    9400                                                  
                        29   14.500                                       
                                   --    0.7  50                          
Immunoadsorbent                                                           
Pool resulting from                                                       
           1020  4.6                                                      
                    4692                                                  
                        --   --    50    --   --                          
Immunoadsorbent                                                           
Pool After Initial                                                        
            20  134 2680                                                  
                        --   --    29(57)                                 
                                         --   --                          
Concentration                                                             
Sum Resulting from                                                        
           --   --  1576                                                  
                        --   --    17(59)                                 
                                         --   --                          
Aminohexyl Column                                                         
Aminohexyl 0.95 1172                                                      
                    1112                                                  
                        0.51 0.48  12    2294 163.857                     
Fraction #3                                                               
Aminohexyl --   545 --  0.23 --    --    2370 169.285                     
Fraction #4                                                               
__________________________________________________________________________
 *A frozen human plasma pool used as the standard for VIIIC assays and    
 assigned the value of 1 human unit per ml.                               

                                  TABLE II                                
__________________________________________________________________________
VIII:C Obtained From Citrated Porcine Plasma                              
                                         Specific                         
                                              From                        
                VIIIC                                                     
                    VIIIC                Activity                         
                                              Plasma                      
           Volume                                                         
                (Units/                                                   
                    (Total                                                
                        Protein                                           
                             Protein                                      
                                   Recovery                               
                                         (Units/                          
                                              (Fold                       
           (ml) ml) Units)                                                
                        (mg/ml)                                           
                             (Total mg)                                   
                                   (%)   mg)  Purif.)                     
__________________________________________________________________________
Sample Applied to                                                         
           1000  1* 1000                                                  
                        76   76.000                                       
                                   100   0.013                            
                                              --                          
Immunoadsorbent                                                           
Pool Resulting from                                                       
            70  8.8 613 --   --    61    --   --                          
Immunoadsorbent                                                           
Pool After Initial                                                        
           5.76 88  494.5                                                 
                        0.242                                             
                             1.355 49.5   364  28.000                     
Concentration                                                             
Sum Resulting from                                                        
           5.0  49  247 0.035                                             
                             0.175 25    1413 109.000                     
Aminohexyl Column                                                         
__________________________________________________________________________
 *Porcine plasma used as the standard for VIIIC assays and assigned the   
 value of 1 porcine VIIIC unit per ml.
Although only preferred embodiments are specifically illustrated and described herein, it will be appreciated that many modifications and variations of the present invention are possible in light of the above teachings and within the purview of the appended claims without departing from the spirit and intended scope of the invention.

Claims (20)

What is claimed is:
1. An improved method of preparing Factor VIII procoagulant activity protein comprising the steps of
(a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial concentrate source onto particles bound to a monoclonal antibody specific to VIII:RP,
(b) eluting the VIII:C,
(c) adsorbing the VIII:C obtained in step (b) in another adsorption to concentrate and further purify same,
(d) eluting the adsorbed VIII:C, and
(e) recovering highly purified and concentrated VIII:C.
2. A method according to claim 1, wherein the elutant used in each of steps (b) and (d) is a saline solution.
3. The method according to claim 2, wherein the saline solution is calcium chloride.
4. The method according to claim 3, wherein the concentration of said calcium chloride solution used in steps (b) and (d) ranges from about 0.25 M to about 0.5 M.
5. The method according to claim 1, wherein said adsorbent particles in step (a) are agarose.
6. The method according to claim 1, wherein aminohexyl agarose is employed in step (c) as the adsorbent.
7. The method according to claim 6, wherein calcium chloride solution is employed as the elutant in steps (b) and (d), concentration of said calcium chloride solution ranging from about 0.25 M to about 0.5 M in step (b) and from about 0.25 M to about 0.5 M in step (d).
8. An improved immunoadsorbent for isolation and purification of VIII:C from VIII:C/VIII:RP comprising a monoclonal antibody specific to VIII:RP bound to solid particles.
9. The improved immunoadsorbent of claim 8, wherein said solid particles comprise a resin.
10. The improved immunoadsorbent of claim 9, wherein said resin comprises agarose.
11. The improved immunoadsorbent of claim 10, wherein said agarose is cross-linked agarose.
12. The improved immunoadsorbent of claim 11, wherein said immunoadsorbent has a coupling density of 3 to 4 g of monoclonal antibody per liter of agarose.
13. Highly purified and concentrated .Iadd.human or porcine .Iaddend.VIII:C prepared in accordance with the method of claim 1.
14. Highly purified and concentrated .Iadd.human or porcine .Iaddend.VIII:C prepared in accordance with the method of claim 6.
15. In a method for purifying Factor VIII procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate through a chromatographic type column having adsorbent to which is bound monoclonal antibodies which is specific to VIII:RP and eluting the VIII-C therefrom.
16. The method according to claim 15, wherein said adsorbent is agarose and said elutant is a saline solution. .Iadd.
17. A VIII:C of claim 13, wherein said VIII:C is human VIII:C. .Iaddend. .Iadd.18. A VIII:C of claim 14, wherein said VIII:C is human VIII:C. .Iaddend. .Iadd.19. An improved immunoadsorbent of claim 8 wherein said monoclonal antibody remains bound to VIII:RP during elution of VIII:C. .Iaddend. .Iadd.20. An improved immunoadsorbent of claim 19, wherein said elution is carried out with a saline solution. .Iaddend. .Iadd.21. An improved immunoadsorbent of claim 20 wherein said solution contains calcium ions. .Iaddend. .Iadd.22. An improved immunoadsorbent of claim 21, wherein said solution is calcium chloride. .Iaddend. .Iadd.23. An improved immunoadsorbent of claim 22, wherein the concentration of said calcium chloride is from 0.25 M to about 0.5 M. .Iaddend. .Iadd.24. A human VIII:C preparation having a potency in the range of 134 to 1172 units per ml, and
being substantially free of VIII:RP. .Iaddend. .Iadd.25. A human VIII:C preparation of claim 24, wherein the VIII:C concentration is at least 160,000 fold purified relative to VIII:C in plasma. .Iaddend. .Iadd.26. A human VIII:C preparation of claim 24, wherein the ratio of VIII:C to VIII:RP is greater than 100,000 times the ratio in plasma. .Iaddend. .Iadd.27. A human VIII:C preparation of claim 24, wherein said VIII:C is isolated from VIII:C/VIII:RP and 90-100 percent of the VIII:RP has been
removed. .Iaddend. .Iadd.28. A human VIII:C preparation having a specific activity greater than 2240 units/mg. .Iaddend. .Iadd.29. A human VIII:C preparation of claim 28 wherein the potency is in the range of 134 to 1172 units/ml. .Iaddend. .Iadd.30. An improved method of preparing Factor VIII procoagulant activity protein comprising the steps of
(a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial concentrate source onto a substrate to which is bound a monoclonal antibody specific to VIII:RP,
(b) eluting the VIII:C,
(c) adsorbing the VIII:C obtained in step (b) in another adsorption to concentrate and further purify same,
(d) eluting the adsorbed VIII:C, and
(e) recovering highly purified and concentrated VIII:C. .Iaddend.
.Iadd. A method according to claim 30, wherein said substrate is a resin. .Iaddend. .Iadd.32. A method according to claim 30, wherein said substrate is comprised of particles. .Iaddend. .Iadd.33. An improved immunoadsorbent for isolation and purification of VIII:C from VIII:C/VIII:RP comprising a monoclonal antibody specific to VIII:RP bound to a substrate. .Iaddend. .Iadd.34. Highly purified and concentrated human or porcine VIII:C prepared in accordance with the method of claim 30. .Iaddend. .Iadd.35. In a method for purifying Factor VIII procoagulant activity protein from plasma or concentrate, the improvement comprising the step of passing said plasma or concentrate over a substrate to which is bound monoclonal antibodies which are specific to VIII:RP and eluting the VIII:C therefrom. .Iaddend. .Iadd.36. The method according to claim 35, wherein said substrate is agarose and said elutant is a saline solution. .Iaddend.
US06/563,795 1981-12-14 1983-12-21 Ultrapurification of factor VIII using monoclonal antibodies Expired - Lifetime USRE32011E (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US06/563,795 USRE32011E (en) 1981-12-14 1983-12-21 Ultrapurification of factor VIII using monoclonal antibodies
MX9203820A MX9203820A (en) 1981-12-14 1992-06-29 ULTRAPURIFICATION OF FACTOR VIII USING MONOCLONAL ANTIBODIES.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/330,105 US4361509A (en) 1981-12-14 1981-12-14 Ultrapurification of factor VIII using monoclonal antibodies
US06/563,795 USRE32011E (en) 1981-12-14 1983-12-21 Ultrapurification of factor VIII using monoclonal antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/330,105 Reissue US4361509A (en) 1981-12-14 1981-12-14 Ultrapurification of factor VIII using monoclonal antibodies

Publications (1)

Publication Number Publication Date
USRE32011E true USRE32011E (en) 1985-10-22

Family

ID=26987116

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/563,795 Expired - Lifetime USRE32011E (en) 1981-12-14 1983-12-21 Ultrapurification of factor VIII using monoclonal antibodies

Country Status (2)

Country Link
US (1) USRE32011E (en)
MX (1) MX9203820A (en)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831118A (en) 1987-08-07 1989-05-16 Scripps Clinic And Research Foundation Flouroplastic immunoaffinity columns for purification of blood proteins
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5006642A (en) 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5470954A (en) * 1987-03-31 1995-11-28 Baxter International Inc. Ultrapurification process for factor VIII
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5618788A (en) * 1984-04-20 1997-04-08 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5747337A (en) * 1983-03-31 1998-05-05 The Scripps Research Institute Factor VIII coagulant polypeptides and monoclonal antibodies to them
US5783671A (en) * 1984-01-12 1998-07-21 Chiron Corporation Method and composition for preparation of factor VIIIC
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
WO2000032773A1 (en) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20050233321A1 (en) * 2001-12-20 2005-10-20 Hess John W Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
WO2005111083A2 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US20060204442A1 (en) * 2003-09-12 2006-09-14 Bankruptcy Estate Of Ferx, Inc. Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
US20060237679A1 (en) * 2005-04-22 2006-10-26 Effebi S.P.A. Valve-actuator connection plate
WO2006119062A2 (en) 2005-05-03 2006-11-09 Ucb Pharma S.A. Sclerostin epitopes
US7141719B2 (en) 1997-09-09 2006-11-28 Cambia Microbial β-Glucuronidase genes, gene production and uses thereof
US20070110747A1 (en) * 2005-05-03 2007-05-17 Ucb S.A. Binding agents
US7270827B2 (en) 2001-10-26 2007-09-18 University Of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
WO2008031061A2 (en) 2006-09-08 2008-03-13 Amgen Inc. Anti-activin a antibodies and uses thereof
US20080108796A1 (en) * 1998-08-21 2008-05-08 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
US20090074763A1 (en) * 2007-09-17 2009-03-19 Amgen Inc. Method for inhibiting bone resorption
EP2128270A1 (en) 2003-08-08 2009-12-02 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US7700277B2 (en) 2003-07-26 2010-04-20 Astrazeneca Ab Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
US20100168020A1 (en) * 2008-11-26 2010-07-01 Amgen Inc. Stabilized receptor polypeptides and uses thereof
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US20100298418A1 (en) * 2009-05-20 2010-11-25 Veritas Therapeutics Inc. Assay for measuring plasma FGL-2 and methods and uses thereof
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
EP2319941A2 (en) 2005-10-21 2011-05-11 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
EP2386629A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP2520669A2 (en) 2005-02-07 2012-11-07 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
WO2014029012A1 (en) 2012-08-23 2014-02-27 Stemcell Technologies Inc. Compositions and methods for rapid and reversible biomolecular labeling
WO2014031694A2 (en) 2012-08-21 2014-02-27 The Institute Of Molecular Medicine Anti-tau antibodies and methods of making and using in treatment of tauopathies
WO2014121221A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US8999917B2 (en) 2007-03-06 2015-04-07 Amgen Inc. Variant activin receptor polypeptides and uses thereof
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
US9352043B2 (en) 2010-05-14 2016-05-31 Amgen Inc. High concentration antibody formulations
US9447165B2 (en) 2007-03-06 2016-09-20 Amgen Inc. Variant activin IIB receptor
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US9657090B2 (en) 2011-12-28 2017-05-23 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
US9822173B2 (en) 2012-11-21 2017-11-21 Amgen Inc. Heterodimeric immunoglobulins
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie Dap10/12 based cars adapted for rush
EP3511413A1 (en) 2014-07-25 2019-07-17 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
EP3524622A1 (en) 2007-09-10 2019-08-14 Amgen, Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
US10538584B2 (en) 2011-08-04 2020-01-21 Amgen Inc. Methods for treating bone gap defects
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
WO2020104531A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
EP3722321A1 (en) 2013-12-23 2020-10-14 Institut Pasteur Phospholipase for treatment of immunosuppression
WO2021099586A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
EP3889604A1 (en) 2020-04-01 2021-10-06 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
WO2021198503A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
US11414482B2 (en) 2016-11-08 2022-08-16 University Of Miami Anti-secretogranin III (SCG3) antibodies and uses thereof
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
US11576970B2 (en) 2016-03-10 2023-02-14 UCB Biopharma SRL Pharmaceutical formulations
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
US11851483B2 (en) 2014-12-12 2023-12-26 Amgen Inc. Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4137223A (en) * 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
US4203891A (en) * 1977-12-19 1980-05-20 Rock Gail A Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US4272521A (en) * 1979-07-16 1981-06-09 Cutter Laboratories, Inc. Purified immune serum globulin
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
EP0038642A1 (en) * 1980-04-09 1981-10-28 National Research Development Corporation A monoclonal antibody against hepatitis B and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus B and in isolating hepatitus b surface antigen from a sample
US4302445A (en) * 1980-01-18 1981-11-24 Institut Merieux Method for concentrating and purifying antihemophilic factor or factor VIII
US4348315A (en) * 1979-12-20 1982-09-07 Blombaeck E G B Process in purification and concentration of the factor VIII-complex
US4361510A (en) * 1980-05-27 1982-11-30 Cutter Laboratories, Inc. Blood coagulation promoting product
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4361647A (en) * 1980-05-22 1982-11-30 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4364935A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US4364936A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human monocyte antigen and methods of preparing same
US4364937A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human T cell antigen and methods of preparing same
US4364861A (en) * 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
US4373932A (en) * 1980-01-11 1983-02-15 Akzona Incorporated Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
US4137223A (en) * 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4203891A (en) * 1977-12-19 1980-05-20 Rock Gail A Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4272521A (en) * 1979-07-16 1981-06-09 Cutter Laboratories, Inc. Purified immune serum globulin
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4364935A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US4348315A (en) * 1979-12-20 1982-09-07 Blombaeck E G B Process in purification and concentration of the factor VIII-complex
US4364936A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human monocyte antigen and methods of preparing same
US4364937A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human T cell antigen and methods of preparing same
US4373932A (en) * 1980-01-11 1983-02-15 Akzona Incorporated Application of water-dispersible hydrophobic dyes or pigments as labels in immunoassays
US4302445A (en) * 1980-01-18 1981-11-24 Institut Merieux Method for concentrating and purifying antihemophilic factor or factor VIII
EP0038642A1 (en) * 1980-04-09 1981-10-28 National Research Development Corporation A monoclonal antibody against hepatitis B and its production, a hybridoma producing the monoclonal antibody and compositions containing it, the propagation of the hybridoma and the monoclonal antibody for use as an antiviral agent against hepatitus B and in isolating hepatitus b surface antigen from a sample
US4361647A (en) * 1980-05-22 1982-11-30 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
US4361510A (en) * 1980-05-27 1982-11-30 Cutter Laboratories, Inc. Blood coagulation promoting product
US4364861A (en) * 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning

Non-Patent Citations (109)

* Cited by examiner, † Cited by third party
Title
1. Field of the Invention
2. Description of the Prior Art
Abstracts Circulation, vol. 62, Supp. III, (10/80) No. 648, J. A. Katzman et al. *
Abstracts Circulation, vol. 66, Supp. II, Oct. 1982, Fay et al. *
Although Austen, as earlier described, has reported the use of aminohexyl-agarose to separate VIII:C from VIII:RP, such a material has not heretofore been used to concentrate VIII:C following a separation and purification step. Heretofore, the highest VIII:C concentrations achieved by using aminohexyl agarose in chromatography were 0.53 units per ml of eluant for human protein and 2.38 per ml of eluant for porcine VIII:C. The present method permits concentrations several orders of magnitude greater than these. Perhaps of even greater significance, is the fact that the present invention provides for a greater purification of human VIII:C than has ever been reported (164,000 vs 17,000 fold over plasma). The present method, which is described in more detail hereinafter, yields VIII:C with a specific activity of 2,300 units/mg when commercial concentrate is used. This corresponds to a 164,000 fold purification from plasma. The ratio of VIII:C to VIII:RP is greater than 105 as compared to t
Analytical Biochemistry, 111 p. 1 (1981), G. S. Eisenbarth. *
Ann. Rev. Biochemistry 1981, vol. 50, p. 657, D. E. Yelton et al. *
Annal N.Y. Acad. Sci. 370, 210 226, (1981), McKee. *
Annal N.Y. Acad. Sci. 370, 210-226, (1981), McKee.
Another method for separating VIII:C from VIII:RP and ristocetin co-factor by a chromatographic technique employing aminohexyl-substituted agarose has been described by D. E. G. Austen, "The Chromatographic Separation of Factor VIII on Aminohexyl Sepharose," BRITISH JOURNAL OF HAEMATOLOGY, Vol. 43, p. 669 (1979). The described method is stated to be an improved method for the component parts of both human and porcine factor VIII/von Willebrand factor. This method, however, also suffers from the fact that contaminants are present in the resulting product. In both the Tuddenham et al and Austen methods a contaminated product, which is more dilute than is normally desired, is formed.
Arch. Geschwulstforsch, vol. 51/4 p. 302 (1981), M. R. Price et al. *
Biochemistry, vol. 19, No. 3, Feb. 5, 1980, Vehar et al. *
Biochemistry, vol. 20, No. 19, p. 5625 (1981), J. S. Pober et al. *
Biochimica et Biophysica Acta, 668, pp. 456 470, (1981), Harris et al. *
Biochimica et Biophysica Acta, 668, pp. 471 480 (1981), Harris et al. *
Blood 58, 1 (1981), Hoyer. *
Blood, 63, No. 2, 486 489 (1984), Fulcher et al. *
Blood, 63, No. 2, 486-489 (1984), Fulcher et al.
Blood, vol. 58, pp. 530 535 (1981), Katzman et al. *
Blood, vol. 59, No. 3 (3/1982), Goodall et al. *
Blood, vol. 59, No. 3, (3/82), Knutson et al. *
Blood, vol. 59, pp. 594 600 (1982), Fass et al. *
Blood, vol. 61, No. 1 (1/83), Ogata et al. *
British J. of Hematology vol. 43 p. 669 (1979), D. E. G. Austen. *
British J. of Hematology, vol. 40, p. 631 (1978), J. M. Lavergne et al. *
British Journal Cancer, vol. 40 p. 701 (1979), S. Pahlman et al. *
C. R. Seances Acd. Sci. III (France) Abstract, vol. 293 (8) p. 447 (1981), N. Josso et al. *
C.R. Acad. Science Paris t. 293 p. 447 (2 Nov. 1981), N. Josso et al. *
Clin. Exp. Immunology, vol. 42, p. 458 (1980), M. Shigeta et al. *
Clinical Exp. Immunology Abstract vol. 33 (3) p. 425 (1978), D. G. Williams. *
Clinics In Hematology, vol. 8, No. 1, p. 207 (1979), S. Shapiro. *
Eur. J. Immunol., 9:155 159 (1979), Sunderland et al. *
Eur. J. Immunol., 9:155-159 (1979), Sunderland et al.
Factor VIII procoagulant activity protein functions to correct the clotting defect in hemophilic plasma. It circulates in plasma complexed with the von Willebrand factor protein. The latter can alter the platelet function defect in von Willebrand's disease. That portion of the factor VIII von Willebrand factor complex having coagulant activity is referred to as factor VIII procoagulant activity protein, factor VIII-clotting activity or simply VIII:C (the designation of "VIII:C" will be used hereinafter to identify the portion of the factor VIII molecule with such clotting activity.) The other portion of the factor VIII von Willebrand factor complex having the ability to correct the platelet function defect in von Willebrand's disease is referred to as von Willebrand factor, factor VIII-related antigen, VIIIR:Ag, VIII:RP factor. (The description "VIII:RP" will be used hereinafter to identify the platelet correction function of the factor VIII molecule). Although yet unproven, there is e
Fed. Proc. U.S.A. Abstract vol. 40/31 (99) (1981), C. M. Fraser et al. *
Fed. Proc., Abstract 3430, vol. 40, p. 3 (1981), Katzman et al. *
Hence, it is clear that there still exists a need for an improved method for separating and purifying VIII:C from VIII:RP using plasma or concentrates. Therefore, it is an object of the present invention to satisfy such a need.
Hybridoma Antibody Analysis of Molecular Biology of Coagulation Proteins , 34th An. Mt. A.A. Blood Banks (11/3/81), Edgington et al. *
Immunoassays: Clinical Lab. Tech. For The 1980 s, R. M. Nakamura et al. Eds. pp. 339 349 (1980), Zimmerman et al. *
Immunoassays: Clinical Lab. Tech. For The 1980's, R. M. Nakamura et al. Eds. pp. 339-349 (1980), Zimmerman et al.
Immunology, vol. 31, p. 893 (1976), M. O. Bubb et al. *
Immunology, vol. 35, p. 429 (1978), G. N. Abraham. *
In view of the need for identifying the structures of the factor VIII/von Willebrand factor complex, VIII:C and VIII:RP and the important pharmaceutical value of the coagulant activity ascribable to VIII:C, numerous attempts have been made to purify factor VIII and to separate and concentrate VIII:C and VIII:RP. The techniques used are based generally on either immunoadsorption or ion exchange chromatography. Such techniques as heretofore used have had limited success due to the difficulty of desorbing the proteins from the charged ionic material in an undamanged condition or recovering same in suitable quantities.
J. Bio Chemistry Abstract, vol. 256 (9) p. 4433 (1981), D. M. Kranz et al. *
J. Biol. Chem., 248, 3946 (1973), Legaz et al. *
J. Clin. Invest., 73(2), 307 16 (1984), Weinstein et al. *
J. Clin. Invest., 73(2), 307-16 (1984), Weinstein et al.
J. Immunogenet, Abstract, vol. 4 (4) p. 233 (1977), J. M. Moseley et al. *
J. Immunol Abstract, vol. 127 (6) p. 2580 (1981), B. K. Seon. *
J. Lab. Clin. Med. 77, 185 (1971), Hershgold et al. *
J. Lab. Clin. Med., 736 746 (May 1983), Rotblat et al. *
J. Lab. Clin. Med., 736-746 (May 1983), Rotblat et al.
J. Lab. Clin. Med., vol. 89, No. 6, pp. 1295 1305 (6/77), Brockway et al. *
J. Nara Med. Ass. 30, 199 212 (1979), Fujimura. *
J. Nara Med. Ass. 30, 199-212 (1979), Fujimura.
J. of Immunol. Methods, 39, 285 286, 307 308 (1980), Goding. *
J. of Immunol. Methods, 39, 285-286, 307-308 (1980), Goding.
J. of Lab. Clin. Med. vol. 93 p. 40 (1979), Tuddenham et al. *
J. Steroid Bio chemistry Abstract, vol. 15/1 (131 136), H. R. Lindner et al. *
Journal of Bio Chemistry, vol. 254, p. 8709 (1979), P. Parham. *
Journal of Bio. Chemistry, vol. 225, pp. 4980 4983 (1980), J. P. Brown et al. *
Journal of Bio. Chemistry, vol. 225, pp. 4980-4983 (1980), J. P. Brown et al.
Journal of Bio-Chemistry, vol. 254, p. 8709 (1979), P. Parham.
Journal of Chromatography, vol. 86, pp. 53 56 (1973), J. Porath et al. *
Journal of Chromatography, vol. 86, pp. 53-56 (1973), J. Porath et al.
Journal of Clinical Investigation, vol. 50, No. 1, pp. 244 254, (Jan. 1971), Zimmerman et al. *
Journal of Experimental Medicine, 138, No. 4, pp. 1015 1020, (1973), Zimmerman et al. *
Journal of Immunological Methods, vol. 38, p. 239 (1980), W. Romer et al. *
Journal of Immunology, 128, No. 6, 2709 2713 (Jun. 1982), Ehrlich et al. *
Journal of Immunology, 128, No. 6, 2709-2713 (Jun. 1982), Ehrlich et al.
Journal of Steroid Biochemistry, vol. 15 p. 131
Journal of Steroid Biochemistry, vol. 15 p. 131 (1981), H. R. Linder et al. *
Methods Enzymol, vol. 80, pp. 249 274 (1981), Nesheim et al. *
Mol. Immunol Abstract, vol. 18/9 p. 831 (1981), J. Sharon et al. *
Monoclonal Antibodies, Plenum Press, New York, 1980 (Text), pp. 395 397, Kennett et al. *
Monoclonal Antibodies, Plenum Press, New York, 1980 (Text), pp. 395-397, Kennett et al.
Monoclonal Antibodies, Scientific American 243:66 74 (Oct. 1980), Milstein. *
Monoclonal Antibodies, Scientific American 243:66-74 (Oct. 1980), Milstein.
Muller et al., Blood, vol. 58, No. 5, pp. 1000 1006, Nov. 1981. *
Muller et al., Blood, vol. 58, No. 5, pp. 1000-1006, Nov. 1981.
One such method for separating VIII:C from VIII:RP utilizing immunoadsorbent chromatography has been reported by E. G. D. Tuddenham et al, "The Properties of Factor VIII Coagulant Activity Prepared by Immunoadsorbent Chromatography", JOURNAL OF LABORATORY CLINICAL MEDICINE, Vol. 93, p. 40 (1979). The reported method is a one-step separation of VIII:C from nearly all VIII:RP and from most other plasma proteins employing a chromatographic column packed with agarose beads to which polyclonal antisera to VIII:RP (anti-VIII:RP) are coupled. Factor VIII/von Willebrand factor containing plasma is passed through the column which adsorbs both VIII:C and VIII:RP. Other unwanted plasma proteins are removed from the column by washing with buffered saline solution and the desired VIII:C is obtained by subsequent elution with a calcium-ion gradient. Although it is stated to be an improvement in both purity and yield of VIII:C, when compared to the previously known methods, it is also stated that the
Proc. Natl. Acad. Sci. U.S.A., vol. 77, No. 12, p. 7034, (1980) C. M. Fraser. *
Proc. Natl. Acad. Sci. U.S.A., vol. 79, pp. 1648 1652, Mar. 1982. *
Proc. Natl. Acad. Sci. USA, 79, 7200 (1982), Fay et al. *
Proc. Natl. Acad. Sci. USA, vol. 76 p. 1420 (1979), J. Sharon et al. *
Proc. Natl. Acad. Sci. USA, vol. 78, No. 1, p. 162 (1/1981), J. A. Katzman. *
Progress in Hematology, 13, 279 (1983), Zimmerman et al. *
Rev. Med. Interne Abstract, vol. 2/4 (425 429) (1981), Y. Chestier et al. *
Scand. J. Immunol. Abstract, vol. 11/1 p. 37 (1980), E. B. Myhre. *
Science, vol. 222, pp. 721 726 (11/18/83), Teillaud et al. *
Symposium on Factor VIII, Abstract/Presentation, (10/7 9/82), Katzman et al. *
Symposium VIII, Factor VIII/von Willebrand Factor, Abstract No. 0476, Jul. 14, 1981, Fass et al. *
The first step involves immunoadsorption of factor VIII from plasma or a commercial concentrate. The adsorbent employed comprises a monoclonal antibody specific to VIII:RP which is bound to a suitable substrate such as, agarose beads. After the VIII:C/VIII:RP is initially adsorbed, the substrate particles are washed extensively with a buffer solution to remove unadsorbed protein. The adsorbed material is then treated with a calcium ion containing solution to elute the adsorbed VIII:C. The VIII:RP portion remains adsorbed on the anti-VIII:RP bound material. At this point about 40-60% of the VIII:C initially adsorbed is recovered in a highly purified state. However, the procoagulant activity protein recovered, although extremely pure, i.e., largely free from contaminants, is too dilute to be of significant therapeutic value.
The invention described herein was made in the course of work under a grant or award from The Department of Health, Education and Welfare and the Government has certain rights therein. .Iaddend.
The isolation of the antihemophilic factor from blood plasma has been described in the literature. The precise structure of the antihemophilic factor, also referred to as factor VIII procoagulant activity protein (factor VIII), has not yet been identified, due in part to the unavailability of sufficient quantities of pure material with which to conduct further studies. The limited availability of pure material and its existence in a dilute state has also hindered its use in therapeutic applications.
The present invention relates to a method of separation of the component molecules of the factor VIII/von Willebrand factor complex, VIII:C and VIII:RP, and the purification and concentration of the pro-coagulant activity protein VIII:C. The method achieves the object of producing highly purified VIII:C using a two step procedure.
The present method also permits the selection of a monoclonal antibody having a high affinity for VIII:RP; however, the use of polyclonal antibodies results in varying affinities. It should be realized that there is an indirect relationship between the affinity of the bound antibody for VIII:RP and the elution of VIII:RP. Thus, the higher the affinity of the antibody for VIII:RP, the less VIII:RP will be present with VIII:C in the eluant. The present invention also makes it possible to produce an unlimited supply of the specified monoclonal antibody, thus eliminating variations among different batches.
The VIII:C solution obtained from the first step of the present process having a potency of approximately 10-20 International Units (hereinafter "units") is processed in a column containing aminohexyl substituted agarose. The column is then washed with a buffer solution and the VIII:C is eluted with a calcium ion-containing solution to yield a VIII:C concentration in excess of 1000 units per ml, and being greater than 160,000 fold purified from plasma. Thus, the present method yields unexpectedly high purity procoagulant activity protein in a highly concentrated and therapeutically useful state. Methods used heretofore fail to achieve such notable results for several reasons. The method of Tuddenham et al, described earlier, employs bound polyclonal antisera instead of the specific and highly selective monoclonal antibodies to VIII:RP as used in the present invention. As a result, fewer specific antibodies to VIII:RP are coupled for a given weight of agarose. In the method of the prese
This invention relates generally to a method of separating and purifying factor VIII procoagulant activity protein. More specifically, high purity factor VIII procoagulant activity protein is separated from von Willebrand Factor by a two step chromatographic adsorption and concentration technique from plasma or concentrate.
Thromb. Haemost, Abstract 0505, vol. 46, p. 165 (7/12/81), Fass et al. *
Thromb. Haemost, Abstract 0506, vol. 46, p. 166 (7/12/81), Bowie et al. *
Thromb. Haemost., Abstract 0261, vol. 46, p. 88, (7/12/81), Katzman et al. *
Thrombosis Research, 13, No. 3, 409 418 (1978), Lavergne et al. *
Thrombosis Research, 13, No. 3, 409-418 (1978), Lavergne et al.
Thrombosis Research, 8, 777 783 (1976), Brown et al. *
Thrombosis Research, 8, 777-783 (1976), Brown et al.
Thrombosis Research, vol. 12, p. 667 (1978), L. Holmberg et al. *
Thrombosis Research, vol. 20, pp. 85 96 (1980), Muller et al. *
VOPR Virasol, O (2) p. 136 (1981), M. A. Yakhno et al. *

Cited By (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US5747337A (en) * 1983-03-31 1998-05-05 The Scripps Research Institute Factor VIII coagulant polypeptides and monoclonal antibodies to them
US5783671A (en) * 1984-01-12 1998-07-21 Chiron Corporation Method and composition for preparation of factor VIIIC
US5618789A (en) * 1984-04-20 1997-04-08 Genentech, Inc. Functional human factor VIII
US5618788A (en) * 1984-04-20 1997-04-08 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
US5683905A (en) * 1984-04-20 1997-11-04 Genentech, Inc. Vectors and cell lines capable of correctly splicing exon regions
US5654147A (en) * 1984-04-20 1997-08-05 Genentech, Inc. Method of hybridization using oligonucleotide probes
US5633150A (en) * 1984-04-20 1997-05-27 Genentech, Inc. Preparation of functional human factor VIII
US5668108A (en) * 1984-04-20 1997-09-16 Genentech, Inc. Preparation of functional human factor VIII and pharmaceutical treatment therewith
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5470954A (en) * 1987-03-31 1995-11-28 Baxter International Inc. Ultrapurification process for factor VIII
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5006642A (en) 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
US4831118A (en) 1987-08-07 1989-05-16 Scripps Clinic And Research Foundation Flouroplastic immunoaffinity columns for purification of blood proteins
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US20010012626A1 (en) * 1995-08-31 2001-08-09 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US7141719B2 (en) 1997-09-09 2006-11-28 Cambia Microbial β-Glucuronidase genes, gene production and uses thereof
EP2386629A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
EP2386630A1 (en) 1997-10-14 2011-11-16 Darwin Molecular Corporation Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
US20080108796A1 (en) * 1998-08-21 2008-05-08 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
US7659375B2 (en) 1998-08-21 2010-02-09 Immunex Corporation Human IL-1 epsilon DNA and polypeptides
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
WO2000032773A1 (en) 1998-11-27 2000-06-08 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US7758858B2 (en) 1998-11-27 2010-07-20 Darwin Discovery Ltd. Antibodies associated with alterations in bone density
EP2261335A1 (en) 1998-11-27 2010-12-15 UCB Pharma S.A. Compositions and methods for increasing bone mineralisation
US20110150866A1 (en) * 1998-11-27 2011-06-23 Darwin Discovery Limited Compositions and Methods for Increasing Bone Mineralization
US7994299B2 (en) 1998-11-27 2011-08-09 Darwin Discovery Limited Compositions and methods for increasing bone mineralization
US7977312B2 (en) 1998-11-27 2011-07-12 Darwin Discovery Limited Compositions and methods for increasing bone mineralization
US8986685B2 (en) 1998-11-27 2015-03-24 Ucb Pharma S.A. Compositions and methods for increasing bone mineralization
US7572899B2 (en) 1998-11-27 2009-08-11 Ucb Sa Compositions and methods for increasing bone mineralization
US20080234219A1 (en) * 1998-11-27 2008-09-25 Darwin Discovery Limited Compositions and Methods for Increasing Bone Mineralization
US20040158045A1 (en) * 1998-11-27 2004-08-12 Darwin Discovery Ltd. Antibodies associated with alterations in bone density
US9791462B2 (en) 1998-11-27 2017-10-17 Ucb Pharma, S.A. Compositions and methods for increasing bone mineralization
US20040058321A1 (en) * 1998-11-27 2004-03-25 Darwin Discovery Ltd. Compositions and methods for increasing bone mineralization
US20080182788A1 (en) * 1998-11-27 2008-07-31 Darwin Discovery Limited Compositions and Methods for Increasing Bone Mineralization
US7063850B1 (en) 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US20060246083A1 (en) * 1998-12-22 2006-11-02 University Of Tennessee Research Foundation Protective antigen of group a streptococci
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20050058646A1 (en) * 1999-04-01 2005-03-17 Turley Eva A. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyalurons
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP1967525A2 (en) 2001-05-08 2008-09-10 Darwin Molecular Corporation A method for regulating immune function in primates using the foxp3 protein
US7270827B2 (en) 2001-10-26 2007-09-18 University Of Tennessee Research Foundation Multivalent streptococcal vaccine compositions and methods for use
US20050233321A1 (en) * 2001-12-20 2005-10-20 Hess John W Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7799523B2 (en) 2002-04-03 2010-09-21 Celltech R & D, Inc. Association of polymorphisms in the SOST gene region with bone mineral density
US8992911B2 (en) 2003-06-16 2015-03-31 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US9657095B2 (en) 2003-06-16 2017-05-23 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8563271B2 (en) 2003-06-16 2013-10-22 Ucb Manufacturing, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US20110195453A1 (en) * 2003-06-16 2011-08-11 Ucb Manufacturing, Inc. Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
US7985834B2 (en) 2003-06-16 2011-07-26 Celltech R & D, Inc. Compositions and methods for increasing bone mineralization
US20110206678A1 (en) * 2003-06-16 2011-08-25 Ucb Manufacturing, Inc. Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization
EP2341071A1 (en) 2003-06-16 2011-07-06 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
US7868134B2 (en) 2003-06-16 2011-01-11 Ucb Manufacturing, Inc. Immunogenic peptides derived from sclerostin
EP2338906A1 (en) 2003-06-16 2011-06-29 UCB Manufacturing, Inc. Compostion and methods for increasing bone mineralization
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US9011856B2 (en) 2003-06-16 2015-04-21 Ucb Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US11702468B2 (en) 2003-06-16 2023-07-18 Ucb Pharma, S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7700277B2 (en) 2003-07-26 2010-04-20 Astrazeneca Ab Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy
EP2128270A1 (en) 2003-08-08 2009-12-02 Genenews Inc. Osteoarthritis biomarkers and uses thereof
US20060204442A1 (en) * 2003-09-12 2006-09-14 Bankruptcy Estate Of Ferx, Inc. Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
WO2005111083A2 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
EP2520669A2 (en) 2005-02-07 2012-11-07 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
US20060237679A1 (en) * 2005-04-22 2006-10-26 Effebi S.P.A. Valve-actuator connection plate
US20070110747A1 (en) * 2005-05-03 2007-05-17 Ucb S.A. Binding agents
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20090304713A1 (en) * 2005-05-03 2009-12-10 Amgen Inc. Binding agents
EP2325200A1 (en) 2005-05-03 2011-05-25 UCB Pharma S.A. Sclerostin binding agents
EP2325199A1 (en) 2005-05-03 2011-05-25 UCB Pharma S.A. Sclerostin binding agents
EP2301961A1 (en) 2005-05-03 2011-03-30 UCB Pharma, S.A. Sclerostin epitopes
US10273293B2 (en) 2005-05-03 2019-04-30 Amgen Inc. Method for inhibiting bone resorption
EP2298800A1 (en) 2005-05-03 2011-03-23 UCB Pharma, S.A. Sclerostin binding antibodies
EP2295448A1 (en) 2005-05-03 2011-03-16 UCB Pharma, S.A. Sclerostin epitopes
EP3985015A1 (en) 2005-05-03 2022-04-20 UCB Pharma S.A. Sclerostin binding agents
US7872106B2 (en) 2005-05-03 2011-01-18 Amgen Inc. Sclerostin-binding antibodies
EP2264063A1 (en) 2005-05-03 2010-12-22 UCB Pharma, S.A. Sclerostin binding antibody
US20070072797A1 (en) * 2005-05-03 2007-03-29 Ucb S.A. Epitopes
US8637643B2 (en) 2005-05-03 2014-01-28 Ucb Pharma, S.A. Sclerostin binding antibody
US9296812B2 (en) 2005-05-03 2016-03-29 Amgen Inc. Sclerostin binding antibodies
US10562964B2 (en) 2005-05-03 2020-02-18 Amgen Inc. Methods for isolating antibodies that bind sclerostin
US20110097342A1 (en) * 2005-05-03 2011-04-28 Amgen Inc. Binding agents
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US9089553B2 (en) 2005-05-03 2015-07-28 Amgen Inc. Method for inhibiting bone resorption
US8715663B2 (en) 2005-05-03 2014-05-06 Amgen Inc. Epitopes
WO2006119062A2 (en) 2005-05-03 2006-11-09 Ucb Pharma S.A. Sclerostin epitopes
EP3670528A1 (en) 2005-05-03 2020-06-24 UCB Pharma S.A. Sclerostin binding agents
US11939372B2 (en) 2005-05-03 2024-03-26 Amgen Inc. Binding agents
US8383801B2 (en) 2005-05-03 2013-02-26 Amgen Inc. Polynucleotide encoding a sclerostin-binding antibody
US9353174B2 (en) 2005-05-03 2016-05-31 Amgen Inc. Epitopes
EP2319941A2 (en) 2005-10-21 2011-05-11 GeneNews Inc. Method and apparatus for correlating levels of biomarker products with disease
US20070258908A1 (en) * 2006-04-27 2007-11-08 Lanza Gregory M Detection and imaging of target tissue
EP3495388A1 (en) 2006-09-08 2019-06-12 Amgen Inc. Anti-activin a antibodies and uses thereof
EP2559705A2 (en) 2006-09-08 2013-02-20 Amgen Inc. Anti-activin a antibodies and uses thereof
EP3133084A1 (en) 2006-09-08 2017-02-22 Amgen Inc. Anti-activin a antibodies and uses thereof
WO2008031061A2 (en) 2006-09-08 2008-03-13 Amgen Inc. Anti-activin a antibodies and uses thereof
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2423226A2 (en) 2006-11-10 2012-02-29 Amgen Inc. Antibody-based diagnostics and therapeutics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
US9447165B2 (en) 2007-03-06 2016-09-20 Amgen Inc. Variant activin IIB receptor
US8999917B2 (en) 2007-03-06 2015-04-07 Amgen Inc. Variant activin receptor polypeptides and uses thereof
US9809638B2 (en) 2007-03-06 2017-11-07 Amgen Inc. Variant activin receptor
US10407487B2 (en) 2007-03-06 2019-09-10 Amgen Inc. Variant activin receptor
US9610327B2 (en) 2007-03-06 2017-04-04 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP3141605A1 (en) 2007-03-06 2017-03-15 Amgen, Inc Variant activin receptor polypeptides and uses thereof
EP3524622A1 (en) 2007-09-10 2019-08-14 Amgen, Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8440193B2 (en) 2007-09-17 2013-05-14 Amgen Inc. Method for inhibiting bone resorption
US11091537B2 (en) 2007-09-17 2021-08-17 Amgen Inc. Method for inhibiting bone resorption
US20090074763A1 (en) * 2007-09-17 2009-03-19 Amgen Inc. Method for inhibiting bone resorption
US8329176B2 (en) 2007-09-17 2012-12-11 Amgen Inc. Method for inhibiting bone resorption
US8017120B2 (en) 2007-09-17 2011-09-13 Amgen Inc. Method for inhibiting bone resorption
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
US20100168020A1 (en) * 2008-11-26 2010-07-01 Amgen Inc. Stabilized receptor polypeptides and uses thereof
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
EP3101029A1 (en) 2008-11-26 2016-12-07 Amgen, Inc Variants of activin iib receptor polypeptides and uses thereof
US11685770B2 (en) 2008-11-26 2023-06-27 Amgen Inc. Stabilized receptor polypeptides and uses thereof
US8410043B2 (en) 2008-11-26 2013-04-02 Atara Biotherapeutics, Inc. Stabilized activin IIB receptor polypeptides and uses thereof
US10308704B2 (en) 2008-11-26 2019-06-04 Amgen Inc. Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
US20100298418A1 (en) * 2009-05-20 2010-11-25 Veritas Therapeutics Inc. Assay for measuring plasma FGL-2 and methods and uses thereof
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
US11040102B2 (en) 2010-05-14 2021-06-22 Amgen Inc. High concentration antibody formulations
US9352043B2 (en) 2010-05-14 2016-05-31 Amgen Inc. High concentration antibody formulations
US10064946B2 (en) 2010-05-14 2018-09-04 Amgen Inc. High concentration antibody formulations
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
US9617333B2 (en) 2011-03-25 2017-04-11 Amgen Inc. Sclerostin antibody crystals and formulations thereof
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
US9920114B2 (en) 2011-03-25 2018-03-20 Amgen Inc. Antibody formulations
US10538584B2 (en) 2011-08-04 2020-01-21 Amgen Inc. Methods for treating bone gap defects
US9657090B2 (en) 2011-12-28 2017-05-23 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9913900B2 (en) 2011-12-28 2018-03-13 Amgen Inc. Method of treating alvelor bone loss through the use of anti-sclerostin antibodies
US10799583B2 (en) 2012-07-05 2020-10-13 Ucb Pharma, S.A. Treatment for bone diseases
US11896667B2 (en) 2012-07-05 2024-02-13 Ucb Pharma S.A. Treatment for bone diseases
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
WO2014031694A2 (en) 2012-08-21 2014-02-27 The Institute Of Molecular Medicine Anti-tau antibodies and methods of making and using in treatment of tauopathies
WO2014029012A1 (en) 2012-08-23 2014-02-27 Stemcell Technologies Inc. Compositions and methods for rapid and reversible biomolecular labeling
US11466078B2 (en) 2012-11-21 2022-10-11 Amgen Inc. Heterodimeric immunoglobulins
US10233237B2 (en) 2012-11-21 2019-03-19 Amgen Inc. Heterodimeric immunoglobulins
US9822173B2 (en) 2012-11-21 2017-11-21 Amgen Inc. Heterodimeric immunoglobulins
EP3985024A1 (en) 2013-02-01 2022-04-20 Atara Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
US11541070B2 (en) 2013-02-01 2023-01-03 Atara Biotherapeutics, Inc. Administration of an anti-activin-A compound to a subject
WO2014121221A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
EP3722321A1 (en) 2013-12-23 2020-10-14 Institut Pasteur Phospholipase for treatment of immunosuppression
WO2015175340A1 (en) 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
EP3511413A1 (en) 2014-07-25 2019-07-17 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US11851483B2 (en) 2014-12-12 2023-12-26 Amgen Inc. Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
US11576970B2 (en) 2016-03-10 2023-02-14 UCB Biopharma SRL Pharmaceutical formulations
US11414482B2 (en) 2016-11-08 2022-08-16 University Of Miami Anti-secretogranin III (SCG3) antibodies and uses thereof
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie Dap10/12 based cars adapted for rush
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
WO2019166412A1 (en) 2018-02-27 2019-09-06 Diaccurate Modulation of pla2-g1b in therapy
WO2019166413A1 (en) 2018-02-27 2019-09-06 Diaccurate Inhibitors of pla2-g1b cofactors for treating cancer
US11858983B2 (en) 2018-03-30 2024-01-02 Amgen Inc. C-terminal anti-sclerostin antibody variants
US11466079B2 (en) 2018-03-30 2022-10-11 Amgen Inc. C-terminal antibody variants
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
WO2020104531A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
WO2020161165A1 (en) 2019-02-06 2020-08-13 Diaccurate Methods and compositions for treating cancer
WO2021099586A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
EP3889604A1 (en) 2020-04-01 2021-10-06 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
WO2021198503A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer

Also Published As

Publication number Publication date
MX9203820A (en) 1992-07-01

Similar Documents

Publication Publication Date Title
USRE32011E (en) Ultrapurification of factor VIII using monoclonal antibodies
US4361509A (en) Ultrapurification of factor VIII using monoclonal antibodies
US6627737B1 (en) Factor IX purification methods
EP0561427B1 (en) Monoclonal antibodies to new factor VIII coagulant polypeptides
CA1083959A (en) Process for producing intravenous immune globulin
US5639857A (en) Ultrapurification of factor IX and other vitamin k-dependent proteins
Kovács et al. Medicinal chemistry meets proteomics: fractionation of the human plasma proteome
US5055557A (en) Ultrapurification of factor IX and other vitamin K-dependent proteins
US4670543A (en) Process for obtaining complex FVIII/vWF of therapeutical use and resulting products
CA1252744A (en) Ultrapurification of factor ix and other vitamin k- dependent proteins
US5047503A (en) Thrombin-binding substance and process for its preparation
US20150315263A1 (en) Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof
CN115651081A (en) Purification method of tetanus antitoxin, chromatographic packing and tetanus antitoxin
EP0271810A2 (en) Immunological determination of free human protein s and c4bp-protein s complex
Olson Affinity chromatography
EP0217061B1 (en) Ultrapurification of factor VIII
CA1251152A (en) Ultrapurification of factor viii
CA1151542A (en) Process for preparing the third component of the complement from human blood plasma
Jiang et al. Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system.
JP5067917B2 (en) Separation and purification method of ADAMTS13
CA1065305A (en) PROCESS FOR THE ENRICHMENT OF THE PREGNANCY-SPECIFIC .beta.1-GLYCOPROTEIN
JPH0459797A (en) Purification of antibody
JPS5917354A (en) Adsorbent for affinity chromatography
Larsson Purification of antibodies
Subramanian Immunoaffinity chromatography

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: FACTOR VIII:C (MONOCLATE); REQUESTED FOR 952 DAYS

Filing date: 19871217

Expiry date: 20021130

PTER Rejection of a request for patent term extension (for eg. ineligible, dismissal, withdrawal, etc)

Free format text: PRODUCT NAME: FACTOR VIII:C (MONOCLATE)

Filing date: 19871217

Expiry date: 20021130

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: SCRIPPS RESEARCH INSTITUTE, THE, A CORP. OF CA, CA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SCRIPPS CLINIC AND RESEARCH FOUNDATION;REEL/FRAME:006167/0046

Effective date: 19911030

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12